HEALTH PROFESSIONAL · SOURCE READING

EGFR tyrosine kinase inhibitors (TKIs) with or without chemotherapy (for patients with EGFR variants)

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC (First-Line Therapy)

Select patients with activating EGFR variants may benefit from single-agent EGFR TKIs. Randomized controlled trials of patients with chemotherapy-naïve NSCLC and EGFR variants have shown that EGFR inhibitors alone improved both PFS and OS and have favorable toxicity profiles compared with combination chemotherapy. The combination of EGFR TKIs with chemotherapy showed improved PFS compared with EGFR TKI monotherapy and represents another treatment option.

Continue within this section

Osimertinib alone →Osimertinib plus chemotherapy →Amivantamab plus lazertinib →Dacomitinib →Gefitinib →Erlotinib →Afatinib →

Preserved source evidence · Not medical advice